secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001628280-26-026642
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Pharmaceuticals appoints Dr. Charles Duncan to Board of Directors effective April 22, 2026
--------------------------------------------------------------------------------

- Board expands from six to seven members; Duncan appointed as Class II director with term ending at 2026 annual meeting.
- Initial RSU award of $390,000 vests quarterly over four years; annual cash retainer of $50,000.
- Additional annual RSU award of $260,000 after each annual meeting starting 2026, vesting one year later.
- Duncan previously Managing Director at Cantor Fitzgerald, covering >70 biotech companies; founded Sulci Advisors in Sep 2025.
- Duncan cites recent approvals of NEREUS and BYSANTI, label expansion for Fanapt, and pipeline catalysts over next 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026026642/0001628280-26-026642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026026642/vnda-20260422.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-026642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer